Development of ebselen for the treatment of sensorineural hearing loss and tinnitus.

The global impact of hearing loss and related auditory dysfunction including tinnitus and hyperacusis on human health is significant and growing. A substantial body of literature has found that these hearing diseases and disorders result from significant number of genetic variations and molecular mechanisms. Investigational new drugs have been tested and several approved drugs have been repurposed in clinical trials, but no therapeutics for any auditory related indication have been FDA approved.

Ototoxicity in cystic fibrosis patients receiving intravenous tobramycin for acute pulmonary exacerbation: Ototoxicity following tobramycin treatment.

Aminoglycosides are commonly used to treat infections in CF patients and are highly ototoxic. The incidence of tobramycin-induced hearing loss, tinnitus, vertigo or dizziness (ototoxicity) varies widely from 0 to 56% secondary to variation in patient enrollment, dosing, audiometry, and ototoxic criteria. The aim of this study is to determine the incidence of ototoxicity after one course of once-daily IV tobramycin in CF patients.

A Comparison of the NCDB and SEER Database for Research Involving Head and Neck Cancer.

Objective: To determine whether structural differences in data sampling between the National Cancer Database (NCDB), a non-population-based cancer registry, and Surveillance, Epidemiology, and End Results (SEER), a population-based cancer registry, result in differences in patient characteristics or oncologic outcomes.

Study Design: Retrospective cohort study.

Setting: NCDB and SEER database.

Publishing Trends in Otology and Neurotology.

Objectives: 1) Describe publishing trends for otologic/neurotologic disorders over a 35-year span. 2) Compare trends in publishing with disease prevalence. 3) Evaluate changes in topic and journal specific ranking scores over time.

Clinical features of ectomesenchymal chondromyxoid tumors: A systematic review of the literature.

Ectomesenchymal chondromyxoid tumors are rare, benign neoplasms of the head and neck most commonly found within the oral cavity. While histopathological evaluation has been the primary focus of prior studies, clinical characterization of this rare entity currently remains sparse. Thus, this study was performed to provide insights into the clinical characteristics of ectomesenchymal chondromyxoid tumors to aid clinicians in distinguishing the lesion from other benign and malignant processes for a more accurate diagnosis and treatment.